Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.63 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.63 |
| ▸ | USP7 | Q93009 | 2/20 | 0.63 |
| ▸ | STAT3 | P40763 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | NOS2 | P35228 | 8/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12125024 | 1.00 | NFE2L2 (0.63) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12200341 | 0.92 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL84163 | 0.92 | NFE2L2 (0.74) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL84160 | 0.91 | NOS2 (0.63) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12447444 | 0.90 | NFE2L2 (0.62) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL82937 | 0.89 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL82945 | 0.89 | NOS2 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12447479 | 0.89 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL13393866 | 0.89 | CYP3A4 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 | |
| SCHEMBL12136833 | 0.89 | NOS2 (0.73) | NFE2L2MBOAT4USP7STAT3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160175380-A1 | Compositions and Methods of Treatment of Corneal Endothelium Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-06-23 | — | — | US | disclosed |
| US-20150080465-A1 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20130288985-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-8455544-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | Reata Pharmaecuticals, Inc. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | REATA PHARMACEUTICALS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175380-A1 | Compositions and Methods of Treatment of Corneal Endothelium Disorders | FECH, KEAP1, NFE2L2 | NFE2L2 3/4885MBOAT4 4178/4885USP7 3485/4885 |
| US-20130288985-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | FECH, KEAP1, NFE2L2 | NFE2L2 3/4885MBOAT4 4178/4885USP7 3485/4885 |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | NFE2L2 12/4885MBOAT4 92/4885USP7 1458/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NFE2L2 315/4885MBOAT4 1458/4885USP7 4046/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NFE2L2 315/4885MBOAT4 1458/4885USP7 4046/4885 |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | LIPG, CYP27A1, CYP11B1 | NFE2L2 315/4885MBOAT4 1458/4885USP7 4046/4885 |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | CYP17A1, HSD11B2, HSD11B1 | NFE2L2 553/4885MBOAT4 619/4885USP7 587/4885 |
| US-20150080465-A1 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | EDNRA, EDNRB, CYP11B1 | NFE2L2 101/4885MBOAT4 1348/4885USP7 1681/4885 |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | KEAP1, NFE2L2, TFAM | NFE2L2 2/4885MBOAT4 3834/4885USP7 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.